Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs Eli Lilly And Co — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.26 (market cap $41.13B), while Eli Lilly And Co trades at $1,162 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 25.3× iShares 7-10 Year Treasury Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares 7-10 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Eli Lilly And Co for 93 Days on average.
| IEF | LLY | |
|---|---|---|
Market Cap | $41.13B | $1.04T |
Volume | 10,340,382 | 3,064,878 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $1.28K |
52-Week Low | $88.92 | $799.57 |
Typical Hold Time | 108 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.295 with a modest 0.21% daily gain amid a challenging bond market environment. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent Treasury yield volatility and bond market selloffs have created headwinds for fixed income ETFs, while dividend distributions continue with recent payouts around $0.31-0.33 per share.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. While current yields provide income appeal, further rate increases could depress prices. Investors face the trade-off between defensive positioning and potential capital depreciation if the bond rout continues.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
